Should-alpha-interferon be included as standard treatment in multiple myeloma?

No abstract is available for this paper.

• Publication year

  1998

• Venue

  European Journal of Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0959-8049(97)10046-6PMID 9624233
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correlation between in vitro and in vivo sensitivity to human leucocyte interferon in patients with multiple myeloma.

  2009cited by this paper
• Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay

  2004cited by this paper
• Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I–II trial

  2004cited by this paper
• Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.

  1998cited by this paper
• Evidence based medicine, a new challenge.

  1997cited by this paper
• Patient preferences for interferon alfa in multiple myeloma.

  1997cited by this paper
• Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.

  1997cited by this paper
• Systematic Reviews: Critical Links in the Great Chain of Evidence

  1997cited by this paper
• Evidence-based medicine: an incomplete method for informing treatment choices

  1997cited by this paper
• Intensive treatment strategies in multiple myeloma.

  1997cited by this paper
• Medicine--a healing or a dying art?

  1996cited by this paper
• Evidence based medicine: what it is and what it isn't

  1996cited by this paper
• Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.

  1996cited by this paper
• Feasibility and toxicity of interferon maintenance therapy after allogeneic BMT for multiple myeloma: a pilot study of the EBMT.

  1996cited by this paper
• A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma

  1996cited by this paper
• Effect of interferon on the health‐related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan–prednisone to melphalan–prednisone + α‐interferon

  1996cited by this paper
• Interferon- 2b Added to Melphalan-Prednisone for Initial and Maintenance Therapy in Multiple Myeloma

  1996cited by this paper
• Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.

  1995cited by this paper
• Review: Bridges between Health Care Research Evidence and Clinical Practice

  1995cited by this paper
• Evidence based medicine: Socratic dissent

  1995cited by this paper
• A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.

  1995cited by this paper
• Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue.

  1995cited by this paper
• The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.

  1995cited by this paper
• Autologous stem cell transplantation in multiple myeloma: Results of the european group for bone marrow transplantation

  1995cited by this paper
• Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.

  1995cited by this paper
• Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma.

  1995cited by this paper
• Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.

  1995cited by this paper
• Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.

  1995cited by this paper
• Interferon alfa‐2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study

  1995cited by this paper
• Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation.

  1995cited by this paper
• Alternating combination chemotherapy and interferon improves survival in poor prognosis multiple myeloma.

  1995cited by this paper
• Myeloma during a decade: clinical experience in a single centre.

  1995cited by this paper
• Phase III Study Comparing Vincristine, Doxorubicin (Adriamycin), and Dexamethasone (VAD) Chemotherapy with VAD Plus Recombinant Interferon Alfa‐2 in Refractory or Relapsed Multiple Myeloma: An Eastern Cooperative Oncology Group Study

  1995cited by this paper
• Grey zones of clinical practice: some limits to evidence-based medicine.

  1995cited by this paper
• Systematic Reviews: Obtaining data from randomised controlled trials: how much do we need for reliable and informative meta-analyses?

  1994cited by this paper
• The treatment of multiple myeloma--an important MRC trial.

  1994cited by this paper
• Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.

  1994cited by this paper
• Randomized clinical trials in oncology: Principles and obstacles

  1994cited by this paper
• Impact of interferon at induction chemotherapy and maintenance treatment for multiple myeloma. Preliminary results of a multicenter study by the Italian non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG).

  1994cited by this paper
• EVOLVING STRATEGIES FOR THE TREATMENT OF MYELOMATOSIS

  1994cited by this paper
• "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up.

  1993cited by this paper
• Double hemibody irradiation (DHBI) in the management of relapsed and primary chemoresistant multiple myeloma.

  1993cited by this paper
• A randomised trial of cyclophosphamide with and without low dose alpha-interferon in the treatment of newly diagnosed myeloma.

  1993cited by this paper
• Recombinant interferon‐ALPHA2b and high dose methyl prednisolone in relapsed and resistant multiple myeloma

  1993cited by this paper
• A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.

  1993cited by this paper
• Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden

  1993cited by this paper
• Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.

  1993cited by this paper
• Combination therapy with interferon‐dexamethasone for newly diagnosed patients with multiple myeloma

  1993cited by this paper
• The current position of allogeneic and autologous BMT in multiple myeloma.

  1992cited by this paper
• Intensive combined therapy for previously untreated aggressive myeloma.

  1992cited by this paper
• Evidence-based medicine. A new approach to teaching the practice of medicine.

  1992cited by this paper
• Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma.

  1992cited by this paper
• Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance

  1992cited by this paper
• Multiple myeloma: Intensified maintenance therapy with recombinant interferon‐α‐2b plus glucocorticoids

  1992cited by this paper
• Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.

  1992cited by this paper
• Recombinant interferon-gamma inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro.

  1991cited by this paper
• Alpha-interferon combination therapy of resistant myeloma.

  1991cited by this paper
• Strategies for combining interferon with chemotherapy for the treatment of multiple myeloma.

  1991cited by this paper
• Maintenance treatment with recombinant alpha interferon after autologous bone marrow transplantation for aggressive myeloma in first remission after conventional induction chemotherapy.

  1991cited by this paper
• alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.

  1991cited by this paper
• Treatment of multiple myeloma with interferon alpha: the Scandinavian experience

  1991cited by this paper
• Strategies for combining interferon with chemotherapy for the treatment of multiple myeloma.

  1991cited by this paper
• Recombinant interferon‐ γ inhibits the growth of IL‐6‐dependent human multiple myeloma cell lines in vitro

  1991cited by this paper
• Interferon in the Treatment of Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group Study.

  1990cited by this paper
• Alpha‐2a‐interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma

  1990cited by this paper
• Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.

  1990cited by this paper
• Recombinant interferon‐alpha combined with prednisone in metastatic renal cell carcinoma reduced toxicity without reduction of the response rate—a phase II study

  1990cited by this paper
• Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.

  1990cited by this paper
• Guidelines for Policy Statements: the Explicit Approach

  1990cited by this paper
• Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.

  1990cited by this paper
• Natural killer cell activity in monoclonal gammopathies: Relation to disease activity

  1990cited by this paper
• Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease.

  1990cited by this paper
• Combination of interferon and dexamethasone in refractory multiple myeloma

  1990cited by this paper
• Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

  1989cited by this paper
• Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.

  1989cited by this paper
• Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes.

  1989cited by this paper
• Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.

  1989cited by this paper
• High doses of natural alpha-interferon (alpha-IFN) in the treatment of multiple myeloma--a pilot study from the Myeloma Group of Central Sweden (MGCS).

  1988cited by this paper
• Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

  1988cited by this paper
• High doses of natural α‐interferon (α‐IFN) in the treatment of multiple myeloma — A pilot study from the Myeloma Group of Central Sweden (MGCS)

  1988cited by this paper
• The medical review article: state of the science.

  1987cited by this paper
• Interferons in the treatment of multiple myeloma

  1987cited by this paper
• Autocrine interferon and the suppression of the c-myc nuclear oncogene.

  1987cited by this paper
• Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies.

  1987cited by this paper
• Treatment of multiple myeloma with recombinant interferon alfa‐2a

  1986cited by this paper
• The effect of alpha and gamma-interferon on proliferation and production of IgE and beta 2-microglobulin in the human myeloma cell line U-266 and in an alpha-interferon resistant U-266 subline.

  1986cited by this paper
• Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial.

  1986cited by this paper
• Treatment of multiple myeloma with recombinant alpha-interferon.

  1986cited by this paper
• Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.

  1986cited by this paper
• The effect of α and γ‐interferon on proliferation and production of IgE and β2‐microglobulin in the human myeloma cell line U‐266 and in an α‐interferon resistant U‐266 subline

  1986cited by this paper
• Phase II study of rDNA alpha-2 interferon (INTRON A) in patients with multiple myeloma utilizing an escalating induction phase.

  1986cited by this paper
• Immunomodulation by interferons: recent developments.

  1985cited by this paper
• Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma.

  1985cited by this paper
• Combined recombinant human interferon alpha2 and cytotoxic agents studied in a clonogenic assay

  1985cited by this paper
• Immunomodulation by interferons: recent developments.

  1985cited by this paper
• Development of transformed phenotype induced by a human ras oncogene is inhibited by interferon.

  1985cited by this paper
• Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system.

  1984cited by this paper
• Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden.

  1984cited by this paper
• Effects of cloned human leukocyte interferons in the human tumor stem cell assay.

  1983cited by this paper
• Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon‐induced enhancement of natural killer activity and clinical response to human interferon‐α

  1982cited by this paper

• Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall

  2014cites this paper
• Practice of Interferon Therapy — Multiple myeloma and other related hematological malignancies—

  2004cites this paper
• Multiple myeloma

  2004cites this paper
• Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.

  2001cites this paper
• Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation

  2001cites this paper
• Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells.

  2001cites this paper
• Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon‐α with melphalan and prednisone (MP) and interferon‐α (IFN‐α) in patients with good‐prognosis multiple myeloma: a prospective randomized study

  2001cites this paper
• Considerations in the management of myeloma.

  2000cites this paper
• Interferons and their Therapeutic Applications

  1999cites this paper
• Multiple myeloma: an update on biology and treatment.

  1999cites this paper
• Current Controversies in CancerShould alpha-interferon be included as standard treatment in multiple myeloma?

  1998cites this paper